A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
NCT ID: NCT05224609
Last Updated: 2024-08-30
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
21 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-04-28
Study Completion Date
2024-08-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Lorlatinib) in health participants. This study is seeking participants who:
* Must be male or female of 18 to 75 years of age, inclusive at the time of the study.
* Are willing and able to comply with all scheduled visits, treatment plan, and other study procedures.
* Have a BMI (body mass index) of 17.5 to 40 kg/m2; and a total body weight \>50 kg (110 lb).
* Are capable of giving signed informed consent document. All participants in this study will receive Lorlatinib. Participants will be placed into 1 of 3 cohorts based on their hepatic (liver) function. Participants will take Lorlatinib once by mouth. We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective. Participants will take part in this study for up to 35 days.
* Must be male or female of 18 to 75 years of age, inclusive at the time of the study.
* Are willing and able to comply with all scheduled visits, treatment plan, and other study procedures.
* Have a BMI (body mass index) of 17.5 to 40 kg/m2; and a total body weight \>50 kg (110 lb).
* Are capable of giving signed informed consent document. All participants in this study will receive Lorlatinib. Participants will be placed into 1 of 3 cohorts based on their hepatic (liver) function. Participants will take Lorlatinib once by mouth. We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective. Participants will take part in this study for up to 35 days.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT
NCT04604496
Hepatic Impairment
Healthy Volunteers
COMPLETED
PHASE1
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
NCT04116476
Mild and Moderate Hepatic Impairment
COMPLETED
PHASE1
A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function
NCT02372084
Hepatic Impairment
COMPLETED
PHASE1
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
NCT04166942
Hepatic Impairment
COMPLETED
PHASE1
Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects
NCT02318836
Liver Failure
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a Phase 1, open label, parallel group study to investigate the effect of moderate and severe hepatic impairment on the plasma PK, safety, and tolerability after a single oral 100 mg dose of lorlatinib under fasted conditions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Moderate Hepatic Impairment
Severe Hepatic Impairment
Healthy Volunteers
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Moderate hepatic impairment group
Group Type
EXPERIMENTAL
Lorlatinib
Intervention Type
DRUG
Single 100mg oral dose anti-cancer agent
Cohort 2
Severe hepatic impairment group
Group Type
EXPERIMENTAL
Lorlatinib
Intervention Type
DRUG
Single 100mg oral dose anti-cancer agent
Cohort 3
Normal hepatic function
Group Type
EXPERIMENTAL
Lorlatinib
Intervention Type
DRUG
Single 100mg oral dose anti-cancer agent
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lorlatinib
Single 100mg oral dose anti-cancer agent
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Lorbrena
PF-06463922
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
All Participants -
1. Participants must be male or female of 18 to 75 years of age, inclusive, at the time of signing the ICD.
2. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
3. BMI of 17.5 to 40 kg/m2; and a total body weight \>50 kg (110 lb).
4. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
1. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, complete physical examination, including BP and pulse rate measurement, 12-lead ECG or clinical laboratory tests. Particularly, should confirm no known or suspected hepatic impairment based on liver function tests (eg, ALT, AST, ALP, and bilirubin), albumin and prothrombin time.
2. Participants must fit the demographic-matching criteria, including: Body weight +- 15 kg of the median of the combined moderate and severe hepatic impairment cohorts (Cohorts 1 and 2), as provided by the sponsor.
Age +- 10 years of the median of the combined moderate and severe hepatic impairment cohorts (Cohorts 1 and 2), as provided by the sponsor.
Comparable male/female ratio to moderate and severe hepatic impairment cohorts (Cohorts 1 and 2).
1. Meet the criteria for Class B (moderate hepatic impairment) of the modified Child-Pugh classification.
2. A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver biopsy, hepatic ultrasound, computerized tomography scan, or MRI.
3. Stable hepatic impairment, defined as no clinically significant known change in disease status within the last 30 days, as documented by the participant's recent medical history (eg, no worsening clinical signs of hepatic impairment, or no worsening of total bilirubin or prothrombin time by more than 50%).
4. Stable drug regimen is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to the dosing of lorlatinib.
5. History of alcohol abuse is permissible providing that the results of alcohol test are negative at Screening or on Day -1, and the participant is willing and able to abide by the lifestyle guidelines.
1. Meet the criteria for Class C (severe hepatic impairment) of the modified Child-Pugh classification.
2. A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver biopsy, hepatic ultrasound, computerized tomography scan, or MRI.
3. Stable hepatic impairment, defined as no clinically significant known change in disease status within the last 30 days, as documented by the participant's recent medical history (eg, no worsening clinical signs of hepatic impairment, or no worsening of TBili or prothrombin time by more than 50%).
4. Stable drug regimen is defined as not starting a new drug or changing dosage within 7 days or 5 half lives (whichever is longer) prior to the dosing of lorlatinib.
5. History of alcohol abuse is permissible providing that the results of alcohol test are negative on Screening or on Day -1, and the participant is willing and able to abide by the lifestyle guidelines.
All Participants -
1. Participants must be male or female of 18 to 75 years of age, inclusive, at the time of signing the ICD.
2. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
3. BMI of 17.5 to 40 kg/m2; and a total body weight \>50 kg (110 lb).
4. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
1. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, complete physical examination, including BP and pulse rate measurement, 12-lead ECG or clinical laboratory tests. Particularly, should confirm no known or suspected hepatic impairment based on liver function tests (eg, ALT, AST, ALP, and bilirubin), albumin and prothrombin time.
2. Participants must fit the demographic-matching criteria, including: Body weight +- 15 kg of the median of the combined moderate and severe hepatic impairment cohorts (Cohorts 1 and 2), as provided by the sponsor.
Age +- 10 years of the median of the combined moderate and severe hepatic impairment cohorts (Cohorts 1 and 2), as provided by the sponsor.
Comparable male/female ratio to moderate and severe hepatic impairment cohorts (Cohorts 1 and 2).
1. Meet the criteria for Class B (moderate hepatic impairment) of the modified Child-Pugh classification.
2. A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver biopsy, hepatic ultrasound, computerized tomography scan, or MRI.
3. Stable hepatic impairment, defined as no clinically significant known change in disease status within the last 30 days, as documented by the participant's recent medical history (eg, no worsening clinical signs of hepatic impairment, or no worsening of total bilirubin or prothrombin time by more than 50%).
4. Stable drug regimen is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to the dosing of lorlatinib.
5. History of alcohol abuse is permissible providing that the results of alcohol test are negative at Screening or on Day -1, and the participant is willing and able to abide by the lifestyle guidelines.
1. Meet the criteria for Class C (severe hepatic impairment) of the modified Child-Pugh classification.
2. A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver biopsy, hepatic ultrasound, computerized tomography scan, or MRI.
3. Stable hepatic impairment, defined as no clinically significant known change in disease status within the last 30 days, as documented by the participant's recent medical history (eg, no worsening clinical signs of hepatic impairment, or no worsening of TBili or prothrombin time by more than 50%).
4. Stable drug regimen is defined as not starting a new drug or changing dosage within 7 days or 5 half lives (whichever is longer) prior to the dosing of lorlatinib.
5. History of alcohol abuse is permissible providing that the results of alcohol test are negative on Screening or on Day -1, and the participant is willing and able to abide by the lifestyle guidelines.
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
All Participants -
1. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
2. History of or current positive results for HIV infection.
3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic (eg. Contact with positive case, residence, or travel to an area with high incidence) that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
4. Participants with an eGFR of ≤ 60 mL/min/1.73 m2 based on the 2021 CKD-EPI equation, with a single repeat permitted to assess eligibility, if needed.
5. Concurrent use of any of the following prohibited concomitant medication(s) within 12 days prior to the first dose of lorlatinib:
1. Known strong CYP3A inhibitors (eg, boceprevir, cobicistat, clarithromycin, conivaptan, diltiazem, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, tipranavir, troleandomycin, voriconazole, grapefruit juice or grapefruit/grapefruit-related citrus fruits \[eg Seville oranges, pomelos\]). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed.
2. Known strong CYP3A inducers (eg, carbamazepine, enzalutamide, mitotane, phenytoin, rifabutin, rifampin, St. John's Wort).
3. Known P-gp substrates with a narrow therapeutic index (eg, digoxin).
6. Concurrent use of CYP3A substrates with narrow therapeutic indices (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl including transdermal patch, pimozide, quinidine, sirolimus, tacrolimus) within 12 days prior to the first dose of lorlatinib.
7. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
8. Known hypersensitivity to lorlatinib or its excipients.
9. A positive urine drug test. Participants with moderate or severe hepatic impairment (Cohorts 1 and 2) will be eligible to participate if their urine drug test is positive with a drug for a prescribed condition that is not expected to interfere with the PK of lorlatinib.
10. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
11. History of sensitivity to heparin or heparin-induced thrombocytopenia.
12. Unwilling or unable to comply with the criteria in the Lifestyle Considerations,
13. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies deemed relevant for participation in this study, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
2. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
3. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If initial supine BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
4. Baseline standard 12-lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline QTcF interval \>450 msec, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree AV block, baseline PR interval \>200, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is \>450 msec, this interval should be rate corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding a participant.
5. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. As an exception, acetaminophen/paracetamol may be used at doses of ≤1 g/day. Limited use of nonprescription medications that are not believed to affect participant safety or the overall results of the study may be permitted on a case by case basis following approval by the Sponsor. Herbal supplements and HRT must have been discontinued at least 28 days prior to the dose of lorlatinib.
6. Participants with a history of or current positive results for hepatitis B or hepatitis C, including HBsAg, HBcAb, or HCVAb.
1. Other clinically significant disease that contraindicates study drug or that may affect the PK of lorlatinib.
2. Hepatic carcinoma and hepatorenal syndrome.
3. Undergone porta-caval shunt surgery.
4. History of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than 1 month prior to study entry.
5. Any clinically significant laboratory abnormality except for those parameters influenced by hepatic impairment.
6. Presence of clinically active Stage 2, 3 or 4 encephalopathy.
7. Severe uncontrolled ascites and/or pleural effusion.
8. Screening supine BP ≥160 mm Hg (systolic) or ≥90 mm Hg (diastolic), on a single measurement following at least 5 minutes of rest. If initial supine BP is ≥160 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the three BP values should be used to determine the participant's eligibility.
9. Screening supine 12-lead ECG demonstrating QTcF \>470 msec. If initial QTcF exceeds 470 msec, the ECG should be repeated two more times and the average of the three QTcF values should be used to determine the participant's eligibility.
10. Second-degree or third-degree AV block (unless paced) or baseline PR interval \>200 msec at any time prior to dosing of study treatment.
All Participants -
1. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
2. History of or current positive results for HIV infection.
3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic (eg. Contact with positive case, residence, or travel to an area with high incidence) that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
4. Participants with an eGFR of ≤ 60 mL/min/1.73 m2 based on the 2021 CKD-EPI equation, with a single repeat permitted to assess eligibility, if needed.
5. Concurrent use of any of the following prohibited concomitant medication(s) within 12 days prior to the first dose of lorlatinib:
1. Known strong CYP3A inhibitors (eg, boceprevir, cobicistat, clarithromycin, conivaptan, diltiazem, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, tipranavir, troleandomycin, voriconazole, grapefruit juice or grapefruit/grapefruit-related citrus fruits \[eg Seville oranges, pomelos\]). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed.
2. Known strong CYP3A inducers (eg, carbamazepine, enzalutamide, mitotane, phenytoin, rifabutin, rifampin, St. John's Wort).
3. Known P-gp substrates with a narrow therapeutic index (eg, digoxin).
6. Concurrent use of CYP3A substrates with narrow therapeutic indices (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl including transdermal patch, pimozide, quinidine, sirolimus, tacrolimus) within 12 days prior to the first dose of lorlatinib.
7. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
8. Known hypersensitivity to lorlatinib or its excipients.
9. A positive urine drug test. Participants with moderate or severe hepatic impairment (Cohorts 1 and 2) will be eligible to participate if their urine drug test is positive with a drug for a prescribed condition that is not expected to interfere with the PK of lorlatinib.
10. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
11. History of sensitivity to heparin or heparin-induced thrombocytopenia.
12. Unwilling or unable to comply with the criteria in the Lifestyle Considerations,
13. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies deemed relevant for participation in this study, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
2. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
3. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If initial supine BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
4. Baseline standard 12-lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline QTcF interval \>450 msec, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree AV block, baseline PR interval \>200, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is \>450 msec, this interval should be rate corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding a participant.
5. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. As an exception, acetaminophen/paracetamol may be used at doses of ≤1 g/day. Limited use of nonprescription medications that are not believed to affect participant safety or the overall results of the study may be permitted on a case by case basis following approval by the Sponsor. Herbal supplements and HRT must have been discontinued at least 28 days prior to the dose of lorlatinib.
6. Participants with a history of or current positive results for hepatitis B or hepatitis C, including HBsAg, HBcAb, or HCVAb.
1. Other clinically significant disease that contraindicates study drug or that may affect the PK of lorlatinib.
2. Hepatic carcinoma and hepatorenal syndrome.
3. Undergone porta-caval shunt surgery.
4. History of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than 1 month prior to study entry.
5. Any clinically significant laboratory abnormality except for those parameters influenced by hepatic impairment.
6. Presence of clinically active Stage 2, 3 or 4 encephalopathy.
7. Severe uncontrolled ascites and/or pleural effusion.
8. Screening supine BP ≥160 mm Hg (systolic) or ≥90 mm Hg (diastolic), on a single measurement following at least 5 minutes of rest. If initial supine BP is ≥160 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the three BP values should be used to determine the participant's eligibility.
9. Screening supine 12-lead ECG demonstrating QTcF \>470 msec. If initial QTcF exceeds 470 msec, the ECG should be repeated two more times and the average of the three QTcF values should be used to determine the participant's eligibility.
10. Second-degree or third-degree AV block (unless paced) or baseline PR interval \>200 msec at any time prior to dosing of study treatment.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Orange County Research Center
Tustin, California, United States
Site Status
Genesis Clinical Research, LLC
Tampa, Florida, United States
Site Status
Prism Research LLC dba Nucleus Network
Saint Paul, Minnesota, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Related Links
Access external resources that provide additional context or updates about the study.
https://pmiform.com/clinical-trial-info-request?StudyID=B7461040
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B7461040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers
NCT03184168
COMPLETED
PHASE1
Evaluate Severe Hepatic Impairment on Dacomitinib PK
NCT03865446
COMPLETED
PHASE1
A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)
NCT01465412
COMPLETED
PHASE1
A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment
NCT02387814
COMPLETED
PHASE1
A Study of JNJ-53718678 in Participants With Hepatic Impairment
NCT04332523
TERMINATED
PHASE1
A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
NCT04752540
COMPLETED
PHASE1
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
NCT04634149
COMPLETED
PHASE1
A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)
NCT02421042
COMPLETED
PHASE1
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
NCT04091061
COMPLETED
PHASE1
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
NCT06908954
RECRUITING
PHASE1
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
NCT03440424
COMPLETED
PHASE1
Effect of Hepatic Impairment on LDE225..
NCT01764776
COMPLETED
PHASE1
A Study of TAK-279 in Adults With or Without Liver Damage
NCT05976321
COMPLETED
PHASE1
Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat
NCT03992014
COMPLETED
PHASE1
Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
NCT04587622
COMPLETED
PHASE1
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
NCT03681457
COMPLETED
PHASE1
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
NCT06813781
COMPLETED
PHASE1
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
NCT04831944
COMPLETED
PHASE1
Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment
NCT04887064
COMPLETED
PHASE1
A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
NCT04772612
COMPLETED
PHASE1
Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment
NCT02170220
COMPLETED
PHASE1
Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment
NCT01594957
COMPLETED
PHASE1
Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects
NCT02231450
COMPLETED
PHASE1
Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
NCT05684653
UNKNOWN
PHASE1